Recent 8-K filings for CVSI

• June 4, 2026, 4:14 PM ET other materiality 0.60 negative item 5.02item 5.07item 9.01 ◈ Shareholder Votes ×3

  CV Sciences shareholders reject reverse stock split; three directors elected

  Proposal 2 (reverse stock split up to 1-for-800) failed: 48.5M for, 59.6M against, 8.1M abstain.

• May 14, 2026, 4:04 PM ET earnings materiality 0.50 neutral item 2.02item 7.01item 9.01

  CV Sciences Q1 revenue down 11.4% to $3.2M; adjusted EBITDA loss narrows to $0.1M

  Revenue $3.2M (down 11.4% YoY); unit sales down 12.2%, partially offset by minor price increases.

• April 10, 2026, 7:59 PM ET debt materiality 0.50 neutral item 1.01item 2.03item 9.01 ◈ Debt Financings ×2◈ Material Agreements ×2

  CV Sciences issues $99,614 senior secured convertible note; conversion price cut to $0.03

  Issued $99,614.04 senior secured convertible note due July 6, 2027 to an institutional investor.

• March 26, 2026, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 7.01item 9.01 ◈ Earnings Releases

  CV Sciences FY2025 revenue down 12% to $13.8M; adjusted EBITDA loss narrows to $0.3M

  Revenue $13.8M for FY2025 vs $15.7M in 2024, a 12.2% decline on lower volume and regulatory headwinds.

• March 10, 2026, 7:59 PM ET debt materiality 0.60 neutral item 1.01item 2.03item 3.02item 9.01 ◈ Debt Financings◈ Material Agreements

  CV Sciences restructures notes: adds conversion at $0.06/share, principal to $2.256M

  Outstanding note principal increased 20% to $2,256,000; monthly redemption obligation eliminated.

• November 13, 2025, 6:59 PM ET earnings materiality 0.60 negative item 2.02item 7.01item 9.01

  CV Sciences Q3 revenue $3.3M (-16% YoY); adjusted EBITDA loss $118K; hemp regulatory language enacted with 1-yr delay

  Revenue $3.3M, down 16% YoY from $3.9M; net revenue from products launched since Jan 2023 contributed 39%.

• October 10, 2025, 7:59 PM ET debt materiality 0.65 neutral item 1.01item 9.01

  CV Sciences issues $600K secured note with $300K net proceeds; potential add'l $750K

  Issued $600K secured promissory note with 25% OID ($150K) plus $150K modification fee; net proceeds $300K.

• September 18, 2025, 7:59 PM ET debt materiality 0.70 neutral item 1.01item 9.01

  CV Sciences amends $1.6M secured note, extends maturity to 2027, defers payments

  Original $1.6M note issued Feb 2025 with $400K OID; outstanding balance $1.28M after $320K payments.

• August 13, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 7.01item 9.01

  CV Sciences Q2 revenue $3.6M (-8% YoY); first positive adjusted EBITDA in six years

  Revenue $3.6M, down 8% from $4.0M in Q2 2024; units sold down 7%, avg price down 2.8%.

• June 5, 2025, 7:59 PM ET other materiality 0.15 neutral item 5.07item 9.01

  CV Sciences annual meeting: directors elected, auditor ratified, say-on-pay approved at 2-year frequency

  Quorum of 54.6% (100.7M of 184.3M shares); directors Corroon, Dowling, McCorkle elected with 17.0M-32.9M votes for.

• May 14, 2025, 7:59 PM ET earnings materiality 0.55 neutral item 2.02item 7.01item 9.01

  CV Sciences Q1 2025 revenue $3.6M (-10% YoY); turns operating profit $11K

  Q1 revenue $3.6M vs $4.0M YoY; unit volume down 11.8%, partially offset by 0.9% price increase.

• March 27, 2025, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 7.01item 9.01

  CV Sciences FY2024 revenue $15.7M (-1.9% YoY), operating loss $2.2M vs income $3.4M in 2023

  Revenue $15.7M vs $16.0M in 2023; Q4 revenue $3.9M (+2.2% YoY).

• February 20, 2025, 6:59 PM ET debt materiality 0.55 neutral item 1.01item 9.01

  CV Sciences issues $1.6M secured promissory note, net proceeds $1.2M

  Principal $1.6M with $400K original issue discount, net $1.2M to company.

• February 19, 2025, 6:59 PM ET litigation materiality 0.65 negative item 8.01

  CV Sciences initiates arbitration against former legal counsel Procopio over faulty RSU tax advice

  Arbitration filed Feb 12, 2025; claims Procopio provided incorrect tax advice on CEO Mona's RSU settlement.

• February 11, 2025, 6:59 PM ET other material materiality 0.70 negative item 1.02item 1.01

  CV Sciences disputes Extract Labs acquisition termination by Sellers; evaluating options

  On Feb 5, 2025, Extract Labs owners informed CV Sciences they cannot close due to alleged failure to obtain bank consent, purportedly terminating the Stock Purchase Agreement.

• November 25, 2024, 6:59 PM ET litigation materiality 0.55 positive item 8.01

  CV Sciences prevails in arbitration against former executive Michael Mona Jr.

  On Nov 20, 2024, arbitrator ruled in favor of CV Sciences and management, denying all claims by Mona.

• November 21, 2024, 6:59 PM ET M&A materiality 0.75 positive item 1.01item 3.02item 7.01item 9.01

  CV Sciences agrees to acquire Extract Labs for $1.4M cash and stock, plus earnout

  Total consideration: $400K cash + $1M in CVSI stock at closing; up to $600K earnout in stock.

• November 14, 2024, 6:59 PM ET earnings materiality 0.55 neutral item 2.02item 7.01item 9.01

  CV Sciences Q3 2024 revenue $3.9M, gross margin 46%, adjusted EBITDA loss of $75k

  Revenue $3.9M, down 5% YoY from $4.1M; B2B sales fell 9% due to state CBD regulations.

• August 13, 2024, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 7.01item 9.01

  CV Sciences Q2 2024 revenue flat at $4.0M; gross margin improves to 47%, adjusted EBITDA near breakeven

  Revenue $4.0M flat YoY and sequentially; B2C sales up 4% offset by B2B decline of 3%.

• July 9, 2024, 7:59 PM ET debt materiality 0.55 neutral item 1.01item 9.01

  CV Sciences enters $1.19M secured note with Streeterville Capital, net proceeds $900K

  Principal amount $1,188,500; net proceeds $900,000 after $283,500 OID and $5,000 fees.

• June 25, 2024, 7:59 PM ET leadership materiality 0.45 neutral item 5.02item 9.01

  CV Sciences enters new 3-year employment agreements with CEO and CFO

  CEO Joseph Dowling new base salary $300K/year, target annual bonus 50% of base.

• June 7, 2024, 7:59 PM ET other material materiality 0.15 neutral item 5.07item 9.01

  CV Sciences stockholders elect directors, ratify auditor, approve exec comp at 2024 annual meeting

  Quorum of 53.1% achieved with 86,682,380 shares represented at June 3, 2024 meeting.

• May 14, 2024, 7:59 PM ET M&A materiality 0.70 positive item 1.01item 3.02item 7.01item 9.01 ◈ Material Agreements

  CV Sciences acquires Elevated Softgels for up to $1M; plans in-sourcing of +PlusCBD production

  Total consideration up to $1,000,000: $100k cash, 17.4M shares ($700k), plus earnout up to $200k.

• May 14, 2024, 7:59 PM ET earnings materiality 0.60 negative item 2.02item 7.01item 9.01 ◈ Earnings Releases

  CV Sciences Q1 2024 revenue $4.0M, gross margin 46.3%, operating loss $0.6M

  Revenue $4.0M, down 4% YoY from $4.1M, up sequentially from $3.8M in Q4 2023.

• March 28, 2024, 7:59 PM ET earnings materiality 0.55 neutral item 2.02item 7.01item 9.01 ◈ Earnings Releases ×2

  CV Sciences FY2023 revenue $16.0M (flat), gross margin improves to 44.3% from 34.2%

  Revenue $16.0M for FY2023, flat vs $16.2M in 2022; Q4 revenue $3.8M down 2% YoY.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.75 · Median 0.60 · Most common event earnings

4 positive 6 negative 15 neutral

source · CVSI on sec.gov